Clinical Trial

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated October 21, 2024 (before its estimated May 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory lymphoma, however not all tumors respond or remain in response to CD19 targeted CAR-T cells. We posit that CAR-T cells expressing BAFF (BAFF CAR-T cells) can become another strategy to treat refractory lymphoma, even after relapse following cluster of differentiation antigen 19 (CD19) targeting CAR-T treatment. This phase 1 study will evaluate safe dose and provide initial signal of the activity of BAFF CAR-T cells against relapsed non-Hodgkin lymphoma using a single lymphodepletion regimen and using a BAFF CAR-T cell manufacturing process.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-04-01; most recent amendment 2024-10-16.
Status change: Not Yet Recruiting → Recruiting 2023-01-11
Trial Details
NCT Number NCT05312801
Lead Sponsor Luminary Therapeutics
Collaborators: Case Comprehensive Cancer Center
Conditions Lymphoma, Non-Hodgkin Lymphoma, B-Cell
Enrollment 20 participants
Start Date 2023-11-21
Primary Completion 2025-05-01 (estimated)
Study Completion 2025-09-02 (estimated)
Updated on ClinicalTrials.gov 2024-10-21